Patents by Inventor James Joseph Onuffer

James Joseph Onuffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250236889
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARS, recognition domains, and/or pH-modulating agents.
    Type: Application
    Filed: April 8, 2025
    Publication date: July 24, 2025
    Applicant: Exuma Biotech Corp.
    Inventors: Gregory Ian FROST, James Joseph ONUFFER, JR., Ghiabe H. GUIBINGA, Farzad HAERIZADEH, Anirban KUNDU
  • Patent number: 12325728
    Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: June 10, 2025
    Assignee: Exuma Biotech Corp.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Ghiabe H. Guibinga, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
  • Patent number: 12258574
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
    Type: Grant
    Filed: May 23, 2023
    Date of Patent: March 25, 2025
    Assignee: Exuma Biotech Corp.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Ghiabe H. Guibinga, Farzad Haerizadeh, Anirban Kundu
  • Publication number: 20250026840
    Abstract: The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.
    Type: Application
    Filed: October 4, 2024
    Publication date: January 23, 2025
    Applicants: Exuma Biotech Corp., BioAtla, Inc.
    Inventors: Gregory Ian FROST, James Joseph ONUFFER, Jr., Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG
  • Patent number: 12187801
    Abstract: The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: January 7, 2025
    Assignees: Exuma Biotech Corp., BioAtla. Inc.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20230392139
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
    Type: Application
    Filed: June 14, 2023
    Publication date: December 7, 2023
    Applicant: Exuma Biotech Corp.
    Inventors: Gregory Ian FROST, James Joseph ONUFFER, Jr., Ghiabe H. GUIBINGA, Farzad HAERIZADEH
  • Publication number: 20230340536
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
    Type: Application
    Filed: May 23, 2023
    Publication date: October 26, 2023
    Applicant: Exuma Biotech Corp.
    Inventors: Gregory Ian FROST, James Joseph ONUFFER, Jr., Ghiabe H. Guibinga, Farzad HAERIZADEH, Anirban KUNDU
  • Publication number: 20230257776
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
    Type: Application
    Filed: April 17, 2023
    Publication date: August 17, 2023
    Applicant: Exuma Biotech Corp.
    Inventors: Gregory Ian FROST, James Joseph ONUFFER, Jr., Ghiabe H. Guibinga, Farzad HAERIZADEH, Anirban KUNDU
  • Publication number: 20230072955
    Abstract: The present disclosure provides chimeric antigen receptors (CARs), and nucleic acids comprising nucleotide sequences encoding the CARs, that bind to HER2, and conditionally active biologic (CAB) CARs that bind to HER2. The present disclosure provides cells genetically modified to produce the CARs, delivery suspensions comprising these genetically modified cells, and methods for making such cells. The CARs of the present disclosure can be used in various methods, which are also provided, including methods for activating immune cells under certain conditions, and methods for performing adoptive cell therapy such as CAR therapy, for example CAR therapy against cancer.
    Type: Application
    Filed: January 23, 2021
    Publication date: March 9, 2023
    Applicants: Exuma Biotech Corp, BioAtla, Inc.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, JR., Anirban Kundu, Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20220340927
    Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells. In some embodiments, the methods include reaction mixtures, and resulting cell formulations, that are created using whole blood, or a component thereof that is not a PBMC, and additionally comprise T cells and recombinant retroviral particles having polynucleotides that encode a CAR. In some embodiments, modified lymphocytes are reintroduced into a subject subcutaneously. In some embodiments, polynucleotides that provide T cells the ability to regulate cell survival and proliferation in response to binding to a CAR, are provided.
    Type: Application
    Filed: August 31, 2020
    Publication date: October 27, 2022
    Applicant: Exuma Biotech Corp.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
  • Publication number: 20220306698
    Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.
    Type: Application
    Filed: April 12, 2022
    Publication date: September 29, 2022
    Applicant: Exuma Biotech Corp.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Ghiabe H. Guibinga, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
  • Patent number: 11325948
    Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: May 10, 2022
    Assignee: Exuma Biotech Corp.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Ghiabe H. Guibinga, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
  • Publication number: 20210403952
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
    Type: Application
    Filed: September 6, 2021
    Publication date: December 30, 2021
    Applicant: EXUMA BIOTECH CORP.
    Inventors: Gregory Ian FROST, James Joseph ONUFFER, Ghiabe H. GUIBINGA, Farzad HAERIZADEH, Anirban KUNDU
  • Publication number: 20210317408
    Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.
    Type: Application
    Filed: September 2, 2019
    Publication date: October 14, 2021
    Applicant: Exuma Biotech Corp.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
  • Patent number: 11111505
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
    Type: Grant
    Filed: July 8, 2017
    Date of Patent: September 7, 2021
    Assignee: EXUMA BIOTECH, CORP.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga, Farzad Haerizadeh, Anirban Kundu
  • Publication number: 20210107949
    Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.
    Type: Application
    Filed: December 2, 2020
    Publication date: April 15, 2021
    Applicant: Exuma Biotech Corp.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
  • Publication number: 20200397821
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
    Type: Application
    Filed: March 3, 2018
    Publication date: December 24, 2020
    Applicant: EXUMA BIOTECH CORP
    Inventors: Gregory Ian FROST, James Joseph ONUFFER, Ghiabe H. GUIBINGA, Farzad HAERIZADEH
  • Publication number: 20200255864
    Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes and related methods that include genetically modifying T cells and/or NK cells. The methods use replication incompetent recombinant retroviral particles that comprise a pseudotyping element on their surface and optionally a membrane-bound T cell activation element, such as an anti-CD3, and encode one or more engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR). The methods can include contacting PBMCs with replication incompetent recombinant retroviral particles for various exemplary time periods, such as less than 24 hours or in some illustrative embodiments less than 15 minutes. In some aspects, the present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in whole blood or a component thereof.
    Type: Application
    Filed: March 18, 2020
    Publication date: August 13, 2020
    Applicant: Exuma Biotech Corp.
    Inventors: Gregory Ian FROST, James Joseph ONUFFER, Farzad HAERIZADEH, Frederic VIGANT, Anirban KUNDU
  • Patent number: 10596274
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.
    Type: Grant
    Filed: March 19, 2017
    Date of Patent: March 24, 2020
    Assignee: Exuma Biotech Corp.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga
  • Publication number: 20190367876
    Abstract: The present disclosure provides methods for genetically modifying and expanding immune cells ex vivo, especially for use in cell-based adoptive immunotherapy. As such, method embodiments are provided for transducing immune cells (e.g. T cells and/or NK cells) that include a step of activating the cells and genetically modifying the activated cells, for example by transducing the cells with recombinant retroviral particles, such as lentiviral particles. Genetically modified cells produced by these methods are also provided. Such methods are typically performed within a closed system, and in illustrative embodiments within a single chamber of a closed system. The methods typically include expanding the genetically modified immune cells in cell expansion media within the closed system, in illustrative embodiments within the single chamber of the closed system. As such, provided herein in illustrative embodiments, are fed-batch, single-reactor method systems.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Applicant: F1 ONCOLOGY, INC.
    Inventors: Gregory Ian FROST, James Joseph ONUFFER